Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

There is no phase 3 trial for EDP-235. It is in a standard risk phase 2.

Wow, you are a genius and an amazing detective to be able to find out something that is obvious.

This won’t work (again, see real clinical results from the Paxlovid trial) and won’t get to phase 3.

You don't understand what the phase 2 trial is about. The phase 2 trial does not have a primary end point regarding patient outcome. It is primarily a safety and dosage assessment trial. You are delusional to think there won't be a phase 3 trial involving the elderly and high risk patients if safety and plasma distribution data are as good in the pase 2 trial as was indicated in the small phase I trial. You also don't seem to understand the advantages of EDP-235 over Paxlovid. EDP-235 doesn't require a drug pump inhibitor and 6 pills a day as Paxlovid does. Rather, EDP-245 will be a one pill a day treatment and NO drug pump inhibitor. You short use all your assets to short ENTA as you are so certain of failure.